Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ocular cicatricial pemphigoid: case report

T D Louie1

  • 1Albuquerque Veterans Administration Medical Center, New Mexico, USA.

Journal of the American Optometric Association
|April 29, 1998
PubMed
Summary

Ocular cicatricial pemphigoid causes conjunctival fibrosis and can lead to blindness. Early diagnosis and consistent monitoring are crucial for managing this progressive autoimmune condition and its complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Visual skills profiles.

Journal of the American Optometric Association·2014
Same journal

Dark adaptation and night blindness.

Journal of the American Optometric Association·2014
Same journal

Scleral tonometry.

Journal of the American Optometric Association·2014
Same journal

Staying in shape: the different roads to fitness for busy optometrists.

Journal of the American Optometric Association·2000
Same journal

Hiring a new optometrist? Be prepared!

Journal of the American Optometric Association·2000
Same journal

Late traumatic intraocular lens extrusion after penetrating keratoplasty.

Journal of the American Optometric Association·2000

Area of Science:

  • Ophthalmology
  • Autoimmune Diseases
  • Dermatology

Background:

  • Ocular cicatricial pemphigoid (OCP) is characterized by subepithelial conjunctival fibrosis, potentially causing symblepharon, entropion, trichiasis, and dry eye.
  • This progressive autoimmune disease can affect ocular tissues, leading to vision loss, and also involve other mucous membranes and skin.
  • Current treatments focus on systemic immunosuppressants and corticosteroids to control inflammation.

Observation:

  • A 69-year-old male patient presented with symblephara, conjunctival shortening, and extraocular manifestations.
  • Diagnosis of OCP was confirmed through clinical presentation and immunofluorescent studies.
  • The patient received treatment with oral Dapsone, prednisone, and azathioprine.

Findings:

  • The case highlights the potential for significant ocular and extraocular manifestations in OCP.
  • Treatment with a combination of immunosuppressants and corticosteroids was initiated to stabilize the patient's condition.
  • Immunofluorescent studies played a key role in confirming the diagnosis.

Implications:

  • Close monitoring of patients with OCP is essential for managing both ocular and extraocular complications.
  • Understanding the progressive nature of OCP is vital for long-term patient care and treatment strategies.
  • This case underscores the importance of a multidisciplinary approach in managing complex autoimmune diseases affecting multiple organ systems.

Related Experiment Videos